ODTX Stock Forecast & Price Target

Odyssey Therapeutics is attractive fundamentally because OD-001 has already shown meaningful de-risking in Phase 2a UC, meeting its primary endpoint with a 2.6-point mMS reduction and producing 27% clinical remission versus about 10% historical placebo, while also showing consistency in AT-experienced patients and a clean safety profile with no Grade 3+ TEAEs, SAEs, or DLTs. Its differentiated RIPK2 scaffolding mechanism targets an upstream innate-immune node that can suppress multiple cytokines at once, supporting both monotherapy and combination potential with vedolizumab, and the company’s broader pipeline in SLC15A4, IRAK4, and TNFR2 adds valuable pipeline optionality. Financially, the company reported $175.7M of cash at the end of March and about $315M of gross IPO and concurrent-financing proceeds, while management/modeling commentary points to 2026 operating expenses of $213.3M and continued near-term cash burn as it advances Phase 2 trials.

Odyssey Therapeutics is a clinical-stage biopharmaceutical company whose valuation rests on highly speculative pipeline success, with lead asset OD-001 only in Phase 2a/b and no assurance that trials will meet primary endpoints or statistical significance. The fundamental bearish case is that efficacy, safety, and regulatory risks are unusually high for novel targets, while commercial competition in autoimmune disease is already intense and physician adoption may favor established biologics over oral small molecules. Financially, the company had only 48 million shares post-IPO, a projected GAAP net loss until 2034, estimated 3Q26 GAAP EPS of $(1.13) and 2026 GAAP EPS of $(6.13), and likely needs about $1.3 billion of additional capital through 2040, making dilution and volatility material concerns.